11:08 AM EDT, 04/01/2024 (MT Newswires) -- Viatris ( VTRS ) on Monday announced the commercial launch of Ryzumvi 0.75%, eye drops used to reverse dilation, in the US.

Ryzumvi, a phentolamine ophthalmic solution used to treat pharmacologically-induced mydriasis, was approved by the Food and Drug Administration in September 2023.

Viatris ( VTRS ) shares were down by nearly 1% in recent trading.

Price: 11.84, Change: -0.10, Percent Change: -0.88